Oncology

Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib.

McKesson to acquire Precision Medicine Group for $2.25bn

US-based healthcare services provider McKesson has agreed to buy Precision Medicine Group for $2.25bn.

Johnson & Johnson’s multiple myeloma treatment secures EC approval

The European Commission (EC) has approved an extended use of Johnson & Johnson’s Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).

WellSpan and Johns Hopkins renew partnership for advanced cancer care access

WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.

BeOne Medicines and partners renew Brukinsa access programme for CLL

BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.

Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status

Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.

FDA grants fast track status to Phanes’ spevatamig for advanced BTC

Phanes Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for spevatamig to treat patients with advanced and metastatic biliary tract carcinoma (BTC).

Xanadu and University of Alberta to develop quantum algorithms for cancer

Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to treat cancer.

BeOne and Revolution Medicines partner for oncology therapies

BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.